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Abstract
Purpose A common and serious problem after living donor
liver transplantation (LDLT) of small grafts is small-for-size
syndrome (SFSS). Although hyperdynamic portal inflow
and portal hypertension are cornerstones in the develop-
ment of SFSS, inadequate outflow may aggravate SFSS.
Therefore, enlargement of the portal outflow tract by
incision of the anterior rim of the orifice of the right
hepatic vein (RHV) has been advocated for right lobe
LDLT. But backwards tilt of a small graft into a large
abdominal cavity may lead to a choking of the otherwise
large anastomosis and thus we propose posterior enlarge-
ment of the orifice of the RHV.
Method In this test-of-concept study, we evaluated portal
vein pressure (PVP), clinical parameters, and laboratory
measurements in 22 patients that underwent right lobe
LDLT and either received standard end-to-end anastomosis
of the RHV or posterior cavoplasty.
Results In patients that underwent posterior cavoplasty,
we observed significantly lower PVP and less hyper-
bilirubinemia. There was a non-significant trend to
lower incidence of SFSS. Other laboratory measure-
ments and clinical parameters were not significantly
different.
Conclusion We recommend posterior cavoplasty for en-
largement of the hepatic venous outflow tract in right lobe
LDLT as a method to avoid portal hypertension, hyper-
bilirubinemia, and possibly SFSS, especially in patients that
receive small grafts.
Keywords Liver transplantation . Complication . Surgical
technique . Clinical trial . Portal hypertension . Living donor
liver transplantation
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Introduction
Small-for-size syndrome (SFSS) injury is a major concern
after living donor liver transplantation (LDLT) [1]. It
manifests as coagulopathy, encephalopathy, intractable
ascites, and prolonged jaundice [2]. SFSS may cause
prolonged hospitalization and graft loss, and thus, survival
rates of patients with small-for-size grafts are worse than
those with adequate graft size [3].
SFSS is frequently encountered in small grafts, i.e.,
grafts with a graft weight- ratio below 0.8%, but may also
be found in recipients of larger grafts [1, 4]. The initial
mechanism of injury seems to be a hyperdynamic portal
flow through a small liver graft, leading to excessive shear
stress injury of sinusoidal cells [5]. Consequently, early
attempts to avert SFSS in small grafts focused on the
diversion or reduction of portal inflow, such as splenic
artery ligation [6], splenectomy [7, 8], mesocaval shunt [9],
or partial portocaval shunt [8, 10, 11]. But Fan and
colleagues also suggest that a pivotal factor may also be a
venous outflow of the graft, because “in the absence of
uniform and adequate outflow, the inflow impedance, graft
hypoperfusion, and therefore, portal hypertension are
aggravated” [1]. Hence, in patients with outflow obstruc-
tion, portal hypertension rather reflects outflow obstruction
and is not the cause of graft injury. It follows that in this
situation, it may even be deleterious to mitigate portal
pressure because it may reduce adequate portal flow that is
also necessary for graft regeneration [12, 13]. Additionally,
Boillot, who was one of the first to describe and widely
adapt portal decompression to avoid SFSS, has retracted
from advocating it in the general situation, because it may
cause insufficient portal inflow and subsequent graft failure
[14].
To address possible outflow obstruction in right liver
grafts, Fan and colleagues [1] advocate anterior incision of
the inferior vena cava (IVC) to enlarge the orifice of the
right hepatic vein (RHV) and prevent outflow obstruction
of the RHV (Fig. 1). But small grafts may also tilt
laterodorsal into a large abdominal cavity, and this may
lead to functional stenosis by choking on the outflow tract
(Fig. 2). Therefore, we enlarged the orifice of the RHV by
oval excision of the posterior sector of the orifice (Fig. 3)
and compared our new technique of posterior cavoplasty to
Fig. 1 Anterior cavoplasty (adapted from [1]). a The transverse
incision line at the anterior sector of the orifice of the right hepatic
vein (RHV) is marked in red. b Orifice has been incised and trimmed
to create an anterior enlargement of the venous outflow tract
Fig. 2 In case of donor–recipient size mismatch, the small graft may
tilt dorsolateral into the large abdominal cavity, and a ridge may
develop at the posterior wall of the orifice of the RHV
Fig. 3 Posterior cavoplasty by oval excision of the posterior sector of
the orifice of the RHV. The anterior rim of the orifice of the MHV is
left and also used for the anastomosis to avoid tension
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conventional end-to-end anastomosis of the RHV in a test-
of-concept study.
Methods
The study included 22 adult patients who underwent LDLT
of the right hepatic lobe between March 2000 and May
2007, of which seven patients were allocated to the control
group and 15 patients to the experimental group that
received the new posterior cavoplasty. The first 14 patients
underwent systematic allocation by alternate assignment to
one of the two study groups in the sequence of their
transplantation (pseudo-randomization). After the first
interim analysis, there were strong indicators that patients
receiving posterior cavoplasty had better clinical outcome,
and we decided to allocate all further patients to the
experimental group for ethical reasons. Sample size
calculations showed that 1:2 allocations would not signif-
icantly increase the type II error while retaining the type I
error at the predefined level.
The patients (6 females and 16 males) had a median age
of 46 (interquartile range (IQR) 41–54), a median body
mass index of 24.7 kg/m2 (IQR 22.2–26.5), and a median
graft-to-recipient weight ratio (percentage of recipient body
weight) of 0.94% (IQR 0.83–1.1). Indication for liver
transplantation included primary cancer of the liver (six
patients), alcoholic liver disease (five patients), hepatitis B
or C virus-related cirrhosis (five patients), cryptogenic
cirrhosis (three patients), primary biliary cirrhosis (two
patients), and acute-on-chronic autoimmune hepatitis (one
patient). Most patients were severely ill, but some were
transplanted primarily due to malignancy without reduced
liver function (11 patients Child-Pugh class C, 3 patients
class B, and 8 patients class A).
Portal pressure was measured after exposure of the
hepatoduodenal ligament by insertion of a 22-gauge needle
into the portal vein. PVP and central vein pressure (CVP)
were measured at the same time in millimeter of mercury
(mmHg). After LDLT, PVP, and CVP were measured again
in the same fashion just before abdominal closure. Graft
function was assessed by daily measurements of total
bilirubin, alanine (ALT), and aspartate transaminase
(AST), gamma-glutamyl transferase (GGT), and prothrom-
bin time (PT) in a standardized fashion. Measurements
were taken from 24 h prior to LDLT until one of the
following endpoints was reached: end of the predefined
study time (20 days), discharge from hospital, re-
transplantation, or death of the patient. For diagnosis of
SFSS, the following criteria were used: prolonged hyper-
bilirubinemia (above 10 mg/dl at POD 14), no signs for
biliary duct obstruction and no proof of rejection, therapy
refractory ascites, coagulopathy (INR>1.5).
Surgery
In the patients allocated to the control group, the anasto-
mosis of the graft hepatic vein was performed in an end-to-
end fashion to the stump of the RHVof the recipient. In the
experimental group, the posterior wall of the orifice of the
RHV was excised 5 mm in transverse and longitudinal axis,
resulting in a laterodorsal position of the caval anastomosis
(Fig. 3). Note also that the anterior sector of the cuff of the
RHV is not trimmed completely to allow for hypertrophy of
the graft without tension at the anastomosis. The RHV is
anastomosed to the orifice with a running 5-0 vascular
suture. Venoplasty of the grafts RHV was not necessary as
all anastomoses could be sewn without tension. In the
experimental group, only tributaries to the middle hepatic
vein larger than 5-mm diameter were reconstructed,
whereas, also smaller tributaries were reconstructed in the
control group to avoid congestion of the right paramedian
sector [15]. The recipient middle and left hepatic veins were
oversewn. The portal vein was anastomosed in typical end-
to-end fashion, and the branch patch technique was used for
anastomosis of the hepatic artery whenever possible. In all
patients, an end-to-end anastomosis of the common bile
duct was created.
Immunosuppression
At the time of transplantation, all patients received
induction immunosuppression with 500-mg methylprednis-
olone and 20-mg basiliximab, the latter was repeated on the
fourth postoperative day (POD). Immunosuppression was
maintained with oral mycophenolat mofetil from the first
POD at 1 g every 12 h and oral prednisolone with an initial
daily dose of 75 mg per day. The latter was tapered by 5 mg
and later 2.5 mg every 2 days to a maintenance dose of
7.5 mg per day. On the fifth POD, oral tacrolimus was
added to the immunosuppressive regimen starting at 0.5 mg
on the first day and increasing daily dose by 1–2 mg to
achieve trough plasma level of 4–10 μg per liter.
Statistical analysis
All statistical calculations were carried out in the R
language and environment for statistical computing (ver-
sion 2.11.0) with type I error fixed at 0.05. The clinical
characteristics of the two groups were represented as
frequencies and percentages for categorial variables and
median and interquartile range (IQR) for continuous
variables. For univariate statistical inference, we used
Fisher's exact test for categorial variables [16] and the
non-parametric Mann–Whitney U test for continuous
variables [17]. For multivariate analysis, we used ordinary
least squares method or linear mixed effects models (LME)
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[18] were appropriate. Package “lme4” (version 0.999375-
33) available in R was used to fit LME. Package
“multcomp” (version 1.1–7) was used to obtain family-
wise confidence intervals for the final model preserving the
overall type I error for multiple comparisons [19]. Daily
laboratory measurements were averaged if there was more
than one measurement per day. Missing values were
substituted by last observation carried forward. For display
of daily mean within groups, a bootstrapped non-parametric
95% confidence interval is provided [20]. Laboratory
measurements at day 20 were also compared by Mann–
Whitney U test.
Kaplan–Meier method was used to estimate overall
patient and graft survival. Differences between groups were
analyzed by log-rank test.
Results
Overall median follow-up was 25.5 months (IQR 12.5–
74.75). Both groups were comparable in terms of age, sex,
body mass index, Child-Pugh score, and diagnosis (Table 1).
Preoperative transaminases were significantly higher in the
experimental group, whereas prothrombin time and total
bilirubin were not different. Patients in the experimental
group had shorter, warm ischemia time but were not different
concerning cold ischemia time, anhepatic time, surgery time,
and graft weight ratio.
Portal vein pressure
Before hepatectomy, recipients had a median PVP of
14.5 mmHg (IQR 13.25–16), and there was no significant
differences between experimental and control group
(p value=0.98; see Fig. 4a). After implantation of the graft,
there is a significant difference of PVP between both
groups (p value<0.001), although CVP is not different (p=
0.43). If we subtract CVP from PVP, we can still see a
significant correlation between treatment group and PVP
(p value=0.004). Concerning the preoperative PVP, we can
see an increase of 3.6 mmHg (p value<0.001, CI 1.7–5.4)
in the control group, whereas PVP decreases in the
experimental group by 4.9 mmHg (p value<0.001,
CI −7.2 to −2.6; Fig. 4b).
Laboratory measurements
Daily measurements of liver function tests show signifi-
cantly lower bilirubinemia in patients that did receive
posterior cavoplasty (p value=0.01 in LME model). AST
Group Control (N=7) Experimental (N=15) P value
Demographic features
Age (yr) 52 (43.5–55) 45 (38.5–53) 0.3
Female sex 1 (14) 5 (33) 0.6
Body mass index (kg/m2) 25.5 (22.1–26.6) 24.6 (22.75–25.95) 0.8
Diagnosis: 0.8
• Cancer 3 (43) 3 (20)
• Alcoholic liver disease 1 (14) 4 (27)
• Chronic viral hepatitis 1 (14) 4 (27)
• Other 2 (29) 4 (27)
Child-Pugh score: 0.6
• A 2 (29) 6 (40)
• B 2 (29) 1 (7)
• C 3 (43) 8 (53)
Preoperative laboratory
Prothombin time (sec) 9.2 (9–9.7) 9.3 (9–10) 0.7
Bilirubine (mg/dl) 1.5 (0.95–2.25) 2.7 (1.3–5.35) 0.4
AST (U/l) 19 (8–26.5) 32 (26–110) 0.02
ALT (U/l) 14 (8.75–21) 36 (20–100) 0.03
Perioperative characteristics
Cold ischemia time (min) 225 (185.5–232) 198 (136.5–268) 0.8
Warm ischemia time (min) 24 (18.5–24) 18 (14–21) 0.06
Anhepatic time (min) 54 (51.5–58) 65 (55–86.5) 0.2
Surgery time (min) 565 (467.5–666.5) 530 (457.5–612.5) 0.8
Graft-weight ratio (%) 1.08 (0.94–1.38) 0.9 (0.82–1.11) 0.23
Table 1 Baseline and perioper-
ative characteristics
Continuous variables are given
in median (interquartile range);
discrete variables are given in
count (percent in group).
P values were derived from test
statistics of Mann–Whitney
U test or Fisher's exact test for
continuous and discrete varia-
bles, respectively
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and ALT were also lower in the experimental group, but
this did not reach statistical significance (p value=0.091
and 0.078 for AST and ALT, respectively; Fig. 5). We did
not observe differences for PT (p value 0.525) and GGT
(p value=0.237).
Clinical outcome
We did not observe primary nonfunction or acute rejection,
but within the study period, one patient died with
functioning graft due to infectious complications, one
patient was re-transplanted on POD 5 in the control group
due to severe graft congestion and one patient in the
experimental group due to hepatic artery thrombosis with
substantial graft necrosis on the 11th POD. We observed
three SFSS in the control group (43%, CI 12–80) and two
SFSS in the experimental group (13%, CI 2–42); the
difference being without statistical significance (p-value=
0.32). SFSS was treated by re-transplantation (one case) or
symptomatic therapy (all other cases) and resolved in all
patients after 3–6 weeks. We also did not observe
significant differences in complications, in-hospital mor-
bidity (p value=0.60 and 0.55, respectively), and length of
Fig. 6 Kaplan–Meier estimate of overall patient survival by study
group. Log-rank test does not show significant differences between
control group (red) and experimental group (blue, p value=0.76)
Fig. 5 Time course of laboratory measurements summarized within
groups (mean and bootstrapped nonparametric 95% confidence
intervals for the estimate). ALT alanine aminotransferase; PT pro-
thrombin time
Fig. 4 Boxplot of portal vein pressure (PVP) before and after
implantation of the graft (a). PVP before implantation is not different
(p value=0.98), whereas PVP after implantation of the graft is
significantly lower in the experimental group (p value<0.001). b
Shows PVP before and after implantation of the graft within groups
and for every single patient. Overall, PVP increases in the control
group by 3.6 mmHg (p value<0.001, CI 1.7–5.4), whereas there is a
decrease by 4.9 mmHg (p value<0.001, CI −7.2 to −2.6) in the
experimental group
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hospital stay (median 35 days, IQR 25–49). Kaplan–Meier
estimates of overall patient survival (Fig. 6) are 77% at
1 year (CI 62–97), 58% at 3 years (CI 40–83), and 52% at
5 years (CI 34–80). Log-rank test does not show significant
differences in patient or graft survival (p value=0.76 and
0.43, respectively). In some patients, computed tomography
(CT) was acquired for follow-up at 6 months or later, and
these did not show significant stenosis at the anastomosis
region in any of the patients of both groups.
Discussion
One of the key features of SFSS is hyperdynamic portal
inflow and portal hypertension. Consequently, early
attempts to avoid SFSS in LDLT aimed at portal decom-
pression [1]. But more and more, it is recognized that portal
decompression may also have deleterious effects on graft
function [14] because liver regeneration is dependent on
adequate graft inflow [12, 13]. Fan and colleagues have
also recognized the paramount importance on adequate
outflow [1]. Outflow obstruction may not only aggravate
inflow impedance but also increase portal hypertension, and
thus mimic SFSS caused by hyperdynamic portal inflow
and portal hypertension. Therapeutic strategies to divert
portal inflow may backfire in this situation, because they
will further reduce portal inflow and may cause a venous
portal steal phenomenon [14]. Although many studies have
shown beneficial effects of portal decompression [6–13], it
has already been recognized that this strategy is not feasible
in all patients receiving partial liver grafts [1, 14] and
should be restricted to patients with increased portal inflow
without outflow obstruction.
Conversely, Fan and colleagues have shown that
optimizing outflow is one of the mainstays to avoid SFSS
and should be attempted in all patients receiving partial
liver grafts [1]. In addition to their elegant surgical
technique of anterior cavoplasty, we propose a posterior
cavoplasty, which should even be more effective in small
grafts. With this new technique, we can show significant
decrease of portal vein pressure, and this results in
significantly less hyperbilirubinemia and lower rate of
SFSS.
There has been much controversy concerning the
management of the MHV and its tributaries [1]. In our
center, it is a common policy to leave the MHV with the
donor to minimize the donor risk but to reconstruct larger
tributaries to the MHV. We decided to also reconstruct
smaller tributaries in the control group, which may explain
longer warm ischemia time compared to the experimental
group. Multivariate analysis did not show any correlation
between warm ischemia time and liver function tests, but
weaker effects may not be excluded in this small cohort.
Small grafts should benefit from the described method of
posterior cavoplasty because the small graft will tilt
backwards in the large abdominal cavity (Fig. 2), and thus,
a ridge will form at the posterior rim of the orifice of the
RHV possibly even if the rim is incised as Fan proposes
[1]. By means of posterior cavoplasty, the orifice of the
RHV is enlarged in the dorsolateral direction, and we may
prevent choking of the outflow tract by backwards tilt in the
early phase after LDLT. Later on growth of the liver should
adjust the functional anastomosis by rectifying the outflow
tract. But regeneration is only possible when there is no
small-for-size graft injury in the early phase. It might also
be possible that in patients with posterior cavoplasty, a
stenosis of the outflow tract will develop after growth of the
liver, but we did not observe this in any of our patients.
In conclusion, we have shown that in this test-of-concept
study, our new method of posterior cavoplasty resulted in
significant reduction of PVP and bilirubinemia and a non-
significant reduction of SFSS. Therefore, we recommend
posterior cavoplasty to avoid venous outflow obstruction
and possibly SFSS in small grafts. We are planning to
confirm the findings of this feasibility study in a larger
cohort of patients.
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